Clinical Trials Logo

Polycystic Ovary Syndrome clinical trials

View clinical trials related to Polycystic Ovary Syndrome.

Filter by:

NCT ID: NCT05592080 Completed - Clinical trials for Polycystic Ovary Syndrome

Exploring Liver and Muscle Fat Content Using MRI

Start date: October 1, 2021
Phase:
Study type: Observational

The aim of our study was to compare the difference of fatty infiltration in liver and muscle using magnetic resonance imaging (MRI) between overweight as well as obese polycystic ovary syndrome (PCOS) cases and body mass index (BMI)-matched women without PCOS, identifying the possible influence factors.

NCT ID: NCT05536583 Completed - Clinical trials for Polycystic Ovary Syndrome

Clinical Efficacy and Safety of Laparoscopic Sleeve Gastrectomy in Obese Patients With PCOS

Start date: May 1, 2013
Phase: N/A
Study type: Interventional

This study aims to evaluate the clinical efficacy and safety in obese patients with Polycystic Ovary Syndrome after laparoscopic sleeve gastrectomy.

NCT ID: NCT05480670 Completed - Clinical trials for Polycystic Ovary Syndrome

Treatment Benefits of Berberine Supplementation for Women With PCOS

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Berberine is a plant alkaloid, reportedly possesses a wide range of pharmacological activities, including anti-obesity and anti-dyslipidemia. Berberine is an effective insulin sensitizer and has a comparable activity to MET in reducing IR. A large body of evidence suggest that Berberine dietary supplementation helps in improvement of symptoms associated with Polycystic Ovary Syndrome (PCOS). The purpose of this study is to investigate the treatment benefits of Berberine in women with PCOS.

NCT ID: NCT05468476 Completed - Clinical trials for Polycystic Ovary Syndrome

Multi-omics Analysis of Women With PCOS and Obesity Compared With Non-PCOS Obese Controls

Start date: May 1, 2019
Phase:
Study type: Observational [Patient Registry]

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in reproductive-aged women, which associated with increased risks to develop metabolic disorders, including cardiovascular diseases, diabetes mellitus, and cerebrovascular diseases. The precise pathogenesis of PCOS remains unknown but is thought to be multifactorial, comprising genetic and environmental factors .

NCT ID: NCT05465135 Completed - Clinical trials for Polycystic Ovary Syndrome

The Effect of Dihydroartemisinin in PCOS

Start date: July 1, 2022
Phase: Phase 4
Study type: Interventional

Artemisinin has been widely used as a first-line antimalarial drug in routine clinical practice. In recent years, it has been reported that Artemisinin also has some significant anti-inflammatory, anti-tumor and immune-modulating effects. The investigators' previous studies discovered that Artemisinin dramatically reduced serum androgen levels and improved poly-cystic ovary syndrome(PCOS) in animals. Preliminary study by the investigators found that artemisinin derivatives are capable of reducing both androgen levels and improving insulin resistance, two clinical characteristics of PCOS. Thus artemisinin derivatives has the potential effect to alleviate PCOS symptoms. The current study aims to investigate the effect of artemisinin on improving PCOS and serum androgen levels in PCOS subjects.

NCT ID: NCT05438355 Completed - PCOS Clinical Trials

The Effect of Polycystic Ovary Syndrome on the Embryo Morphokinetics ( PCOS )

Start date: March 1, 2021
Phase:
Study type: Observational

Polycystic ovarian syndrome (PCOS) is a complex endocrine and metabolic syndrome which accounts for 75% of women with anovulatory infertility. The cause of infertility in PCOS is already unknown. Although efforts have been made, many PCOS patients turned out to have worse oocyte maturity and IVF outcomes. Time-lapse analysis of embryo development can detect the abnormal timeline and cleavage mode which may affect the embryo viability of PCOS. However, there are still some debates on the effect of PCOS on the early embryo development by time-lapse analysis.

NCT ID: NCT05386706 Completed - Clinical trials for Polycystic Ovary Syndrome

Treating PCOS With Digital Intervention vs. Metformin

Start date: June 21, 2022
Phase: N/A
Study type: Interventional

With the change in environment and lifestyle, and the improvement of people's understanding of PCOS, the incidence of PCOS is increasing worldwide. According to statistics, the prevalence of PCOS in premenopausal women is as high as 5-20%. Lifestyle interventions are the main treatment option for patients with PCOS. In addition, research has shown that digital therapy can effectively improve behavior changes in diet, exercise, and medication adherence, predict disease progression, reduce the frequency of disease-related symptoms, and promote effective disease management. This study aimed to investigate the efficacy of digital intervention versus traditional metformin monotherapy in patients with PCOS.

NCT ID: NCT05370521 Completed - Clinical trials for Polycystic Ovary Syndrome

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Start date: May 15, 2022
Phase: Phase 2
Study type: Interventional

An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens

NCT ID: NCT05348265 Completed - Clinical trials for Polycystic Ovary Syndrome

High Intensity Interval Training in PCOS

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Study objective is to determine the effect of High intensity interval training on psychological wellbeing, Anthropometrics and Quality of life in females with Polycystic Ovarian Syndrome

NCT ID: NCT05344547 Completed - Cardiac Disease Clinical Trials

Women With Polycystic Ovary Syndrome Are at High Risk for Cardiac Insults

Start date: March 21, 2020
Phase:
Study type: Observational

Objectives: Evaluation of the cardiovascular (CV) risk in a sample of CV asymptomatic infertile women with polycystic ovary syndrome (PCOS). Patients & Methods: 100 infertile PCOS women older than 30 years (PCOS group) and 50 fertile non-PCOS women (Non-PCOS group) underwent gynecological and laboratory diagnosis and then underwent a diagnostic protocol consisting of determination of body mass index (BMI), Homeostasis model assessment of insulin resistance (HOMA-IR) scoring and cardiologic evaluation using echocardiography, estimation of carotid artery intima-media thickness (CIMT), coronary artery calcium (CAC) score using multi-slice non-contrast cardiac CT and cardiac risk ratio (CRR). Study outcomes included the incidence of abnormal cardiac risk parameters and the determination of the best minimally invasive modality to be used as a screening test for these women.